Menu Search
Equities

Kyowa Kirin Co Ltd

4151:TYO

Kyowa Kirin Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,230.00
  • Today's Change-22.00 / -0.68%
  • Shares traded1.54m
  • 1 Year change+19.54%
  • Beta0.6804
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Kyowa Kirin Co Ltd grew revenues 11.01% from 398.37bn to 442.23bn while net income improved 51.55% from 53.57bn to 81.19bn.
Gross margin74.03%
Net profit margin20.45%
Operating margin23.66%
Return on assets9.50%
Return on equity11.74%
Return on investment10.98%
More ▼

Cash flow in JPYView more

In 2023, Kyowa Kirin Co Ltd increased its cash reserves by 18.84%, or 63.89bn. The company earned 115.55bn from its operations for a Cash Flow Margin of 26.13%. In addition the company used 20.38bn on investing activities and also paid 32.54bn in financing cash flows.
Cash flow per share225.12
Price/Cash flow per share14.56
Book value per share1,634.73
Tangible book value per share1,072.58
More ▼

Balance sheet in JPYView more

Kyowa Kirin Co Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio3.52
Quick ratio3.02
Total debt/total equity0.0294
Total debt/total capital0.0285
More ▼

Growth rates in JPY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 9.80% and 51.53%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)1.74%
Div growth rate (5 year)9.86%
Payout ratio (TTM)31.75%
EPS growth(5 years)10.94
EPS (TTM) vs
TTM 1 year ago		142.79
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.